FOLH1 and metastatic prostate carcinoma: In recent years, the efficacy of RLT using PSMA ligands ([177Lu]Lu-PSMA-617, [177Lu]Lu-PSMA-I&T, and [225Ac]Ac-PSMA-617) in hormone-refractory metastatic prostate cancer (mCRPC) has been reported.